A cancer immunotherapy modality based on dendritic cell reprogramming in vivo
E. Ascic, F. Akerstrom, M. Sreekumar Nair, A. Rosa, I. Kurochkin, O. Zimmermannova, X. Catena, N. Rotankova, C. Veser, M. Rudnik, T. Ballocci, T. Scharer, X. Huang, M. de Rosa Torres, E. Renaud, , C.-F. Pereira
This study reprograms tumor cells in vivo to function as dendritic cells, leading to tumor regression and long-term immunity in mouse models.
bioRxiv · Jul 8, 2024 · PreprintImmunology